Skip to main content
Explore URMC
menu

Frank C. Passero, M.D.

Contact Information

Phone Numbers

Appointment: (585) 276-3000

URMFGA member of the University of Rochester Medical Faculty Group

groupAn Accountable Health Partner

assignmentAccepting New Patients

Faculty Appointments

Patient Care Setting

Cancer

Biography

As a physician I aim to provide patients with an understanding of their medical condition and guidance as they navigate complex medical decisions. I consider honesty, compassion and my medical knowledge as foundational principles upon which I seek to build a trusting patient-physician relationship. Getting to know my patients, their unique circumstances and goals is a key aspect of my practice, in order to provide patients with a personalized plan of care.

I obtained my medical degree from Jefferson Medical College in Philadelphia, Pennsylvania and went on to complete internship, residency, and a chief medical residency in Internal Medicine at Scripps Mercy Hospital in San Diego. I pursued my Hematology and Oncology fellowship training at Tufts Medical Center in Boston, Massachusetts where I carried out laboratory research studying the effects of proteasome and HDAC inhibitors in lymphoma.

I have a special interest in plasma cell disorders including myeloma and amyloidosis, and would like to provide patients with the opportunity to participate in well-designed clinical trials for these and other related diseases.

Credentials

Specialties

  • Hematology - American Board of Internal Medicine
  • Internal Medicine - American Board of Internal Medicine
  • Medical Oncology - American Board of Internal Medicine

Education

2010
MD | Thomas Jefferson University

Post-doctoral Training & Residency

07/01/2014 - 06/30/2017
Fellowship in Hematology/Oncology at Tufts Medical Center

07/01/2011 - 06/30/2014
Residency in Internal Medicine at Mercy Hospital and Medical Center

6/24//2010 - 06/23/2011
Internship in Internal Medicine at Mercy Hospital and Medical Center

VIEW ALL expand_more

Clinical Trials

A Phase II Study of Steroid Sparing Treatment With Daratumumab and Lenalidomide in Newly Diagnosed Transplant Ineligible Patients With Multiple Myeloma

Lead Researcher: Frank C Passero

The purpose of this study is to determine the effects of daratumumab and lenalidomide without steroids for treating patients with multiple myeloma.

View Study Details

A Phase 3, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of CAEL-101 and Plasma Cell Dyscrasia Treatment Versus Placebo and Plasma Cell Dyscrasia Treatment in Plasma Cell Dyscrasia Treatment Naïve Patients With Mayo Stage IIIb AL Amyloidosis

Lead Researcher: Frank C Passero

AL (or light chain) amyloidosis begins in the bone marrow where abnormal proteins misfold and create free light chains that cannot be broken down. These free light chains bind together to form amyloid fibrils that build up in the extracellular space of organs, affecting the kidneys, heart, liver, spleen, nervous system and digestive tract. The primary purpose of this study is to determine if CAEL-101 improves the overall survival in Patients with cardiac AL Amyloidosis.

View Study Details

A Phase 3, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of CAEL-101 and Plasma Cell Dyscrasia Treatment Versus Placebo and Plasma Cell Dyscrasia Treatment in Plasma Cell Dyscrasia Treatment Naïve Patients With Mayo Stage IIIa AL Amyloidosis

Lead Researcher: Frank C Passero

AL (or light chain) amyloidosis begins in the bone marrow where abnormal proteins misfold and create free light chains that cannot be broken down. These free light chains bind together to form amyloid fibrils that build up in the extracellular space of organs, affecting the kidneys, heart, liver, spleen, nervous system and digestive tract. The primary purpose of this study is to determine if CAEL-101 improves the overall survival in Patients with cardiac AL Amyloidosis.

View Study Details

Publications

Journal Articles

11/26/2019
Evens AM, Konry T, David K, Mokhtar M, Chen Y, Beheshti A, Passero F, Purvey S, Sarkar S, Ravi D. "Interaction kinetics with transcriptomic and secretory responses of CD19-CAR natural killer-cell therapy in CD20 resistant non-hodgkin lymphoma." Leukemia.. 2019 Nov 26; Epub 2019 Nov 26.

8/26/2019
Evens AM, David KA, Beheshti A, McDonald JT, Ravi D, Passero FC. "Combinatorial ixazomib and belinostat therapy induces NFE2L2-dependent apoptosis in Hodgkin and T-cell lymphoma." British journal of haematology.. 2019 Aug 26; Epub 2019 Aug 26.

7/29/2019
Lipe B, Passero FC, Gleber C, Portuguese AJ. "A review of thrombotic microangiopathies in multiple myeloma." Leukemia research.. 2019 Jul 29; 85:106195. Epub 2019 Jul 29.

VIEW ALL PUBLICATIONS